Recent Blog Articles

Heart Health

Can a diabetes drug transform the treatment of obesity?

June 01, 2021
In people with obesity, a high-dose weekly injection of the diabetes drug semaglutide caused a 15% weight loss and improved other heart-related risk factors. Semaglutide works by mimicking a substance called GLP-1, which is made naturally by the gut and the brain. It prods the pancreas to release insulin when blood sugar rises too high, reduces appetite, and makes people feel full following a meal.

To continue reading this article, you must log in.

Subscribe to Harvard Health Online for immediate access to health news and information from Harvard Medical School.

  • Research health conditions
  • Check your symptoms
  • Prepare for a doctor's visit or test
  • Find the best treatments and procedures for you
  • Explore options for better nutrition and exercise
Learn more about the many benefits and features of joining Harvard Health Online »

I'd like to receive access to Harvard Health Online for only $4.99 a month.

Sign Me Up

Already a member? Login ».


As a service to our readers, Harvard Health Publishing provides access to our library of archived content. Please note the date of last review or update on all articles. No content on this site, regardless of date, should ever be used as a substitute for direct medical advice from your doctor or other qualified clinician.